Two Democratic lawmakers, Sen. Mark Warner (D-Va.) and Rep. Doris Matsui (D-Calif.), are currently working on a new bill to preserve health providers’ ability to prescribe controlled substances via telehealth. This includes medications such as stimulants for ADHD and buprenorphine for opioid addiction. The urgency behind this bill stems from the impending expiration of temporary waivers originally implemented by the Drug Enforcement Administration (DEA) during the Covid-19 pandemic.
The DEA is considering new regulations that could potentially roll back many of the flexibilities granted during the pandemic. In response, Warner and Matsui’s bill aims to extend the current rules through 2026, according to sources familiar with the legislative effort. This extension is crucial as the flexible rules are scheduled to lapse at the end of the year, posing a threat to patient access to essential medications like stimulants for ADHD and common treatments for opioid addiction.
Telehealth advocates have been vocal about the importance of maintaining these waivers to ensure continued access to necessary medications for patients, especially those managing conditions like ADHD and opioid addiction. The ability for health providers to prescribe controlled substances remotely has proven to be a valuable resource during the pandemic, offering convenience and accessibility to patients in need.
As the landscape of healthcare continues to evolve, telehealth has emerged as a vital tool in expanding access to care and improving patient outcomes. Preserving the ability for health providers to prescribe controlled substances via telehealth not only enhances convenience for patients but also ensures continuity of care for those managing chronic conditions.
The proposed bill by Warner and Matsui underscores the ongoing efforts to modernize healthcare delivery and adapt to the changing needs of patients in a digital age. By extending the current waivers related to telehealth prescriptions, lawmakers are taking proactive steps to safeguard patient access to essential medications and support the continued growth of telehealth as a valuable healthcare resource.
